Nuvation Bio Inc. (NUVB) shares plummeted 14.04% in pre-market trading on Tuesday. The sharp decline follows the biotechnology company's recent fourth-quarter earnings report.
The company reported a quarterly loss of $0.11 per share, which missed the analyst consensus estimate of a $0.09 loss by 22.22%. This earnings miss appears to be the primary driver behind the negative investor sentiment, outweighing the company's quarterly sales of $41.87 million, which surpassed estimates.
Nuvation Bio's net loss for the quarter was reported at $36.6 million. The market's reaction highlights the sensitivity of biotech stocks to earnings performance relative to Wall Street expectations, particularly for companies in the commercial stage like Nuvation Bio.
Comments